公司資料
Amphastar Pharmaceuticals, Inc. 股價、新聞與催化劑
- 股票代碼:
- AMPH
- 交易所:
- NASDAQ
- 產業:
- Pharmaceuticals
- 所在地:
- United States
股票表現
25.35 USD (-1.78%)
收盤價
最後更新: 2026年10月1日
814M USD
市值
股價為何變動
截至 2026年10月1日，AMPH 下跌 1.78%，收於 $25.35。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Specialty Pharmaceutical Manufacturer
Amphastar Pharmaceuticals develops, manufactures, and commercializes technically challenging injectable, inhaled, intranasal, and other pharmaceutical products. Its portfolio combines proprietary brands, complex generics, active pharmaceutical ingredients, and selected biosimilar programs.
Proprietary Products
The company's branded products include BAQSIMI nasal glucagon, Primatene MIST, REXTOVY, Amphadase, and Cortrosyn. These products give Amphastar direct exposure to diabetes rescue, respiratory care, opioid overdose, diagnostic use, and other specialty markets.
Complex Generic Medicines
Amphastar supplies sterile injectables and other complex generics that require specialized development, manufacturing, and regulatory capabilities. Its products are distributed through wholesalers, retailers, hospitals, and group purchasing organizations.
Integrated Manufacturing and APIs
The company manufactures active pharmaceutical ingredients through its ANP subsidiary and operates finished-dose facilities for sterile and nonsterile products. Vertical integration supports supply control, product economics, and development of medicines with technically demanding formulations or devices.
Biosimilar and Proprietary Pipeline
The pipeline includes a filed biosimilar insulin candidate, an additional filed abbreviated new drug application, other biosimilar and generic programs, and in-licensed proprietary peptides for oncology and ophthalmology. Amphastar is also developing a fully synthetic corticotropin compound for inflammatory and autoimmune diseases.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。